Share

November 07, 2017; 89 (19) WriteClick® Editor's Choice

Letter re: Evaluating the safety of β-interferons in MS: A series of nested case-control studies

Peter J. Jongen
First published November 6, 2017, DOI: https://doi.org/10.1212/WNL.0000000000004620
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
24

Share

Article Information

vol. 89 no. 19 2022
DOI: 
https://doi.org/10.1212/WNL.0000000000004620
PubMed: 
29109135
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
0028-3878
Online ISSN: 
1526-632X
History: 
  • First Published November 6, 2017.
Copyright & Usage: 
© 2017 American Academy of Neurology

Author Disclosures

    1. Peter J. Jongen
  1. Peter J. Jongen
  1. Nijmegen, the Netherlands
View Full Text

Article usage

Article usage: October 2017 to April 2022

AbstractFullPdfSource
Oct 2017600Highwire
Nov 201744187Highwire
Dec 20173202Highwire
Jan 2018211Highwire
Feb 20181402Highwire
Mar 2018110Highwire
Apr 2018720Highwire
May 2018701Highwire
Jun 2018500Highwire
Jul 2018300Highwire
Aug 2018600Highwire
Sep 2018601Highwire
Oct 20181400Highwire
Nov 20181001Highwire
Dec 2018800Highwire
Jan 2019400Highwire
Feb 2019500Highwire
Mar 20191412Highwire
Apr 2019526Highwire
May 20191110Highwire
Jun 2019300Highwire
Jul 2019410Highwire
Aug 2019210Highwire
Sep 2019500Highwire
Oct 2019700Highwire
Nov 20192100Highwire
Dec 20191200Highwire
Jan 2020520Highwire
Feb 2020800Highwire
Mar 2020510Highwire
Apr 2020900Highwire
May 2020700Highwire
Jun 20201600Highwire
Jul 20201410Highwire
Aug 2020300Highwire
Sep 2020600Highwire
Oct 20201911Highwire
Nov 20201210Highwire
Dec 2020700Highwire
Jan 2021100Highwire
Feb 20212600Highwire
Mar 20211600Highwire
Apr 20211200Highwire
May 20211100Highwire
Jun 2021100Highwire
Jul 2021600Highwire
Aug 2021800Highwire
Sep 2021100Highwire
Oct 2021900Highwire
Nov 20211000Highwire
Dec 20211500Highwire
Jan 2022700Highwire
Feb 20221100Highwire
Mar 2022600Highwire
Apr 2022900Highwire

Cited By...

Disputes & Debates: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

Alert Me